Illumina is rated a Buy due to strong demand for its consumables and NovaSeq X sequencing instruments, which now account for 59% of consumable revenues, up from 44% in Q2 2025. This growth positions Illumina well to capture a larger share of the expanding diagnostic consumables market. Management projects 2026 revenue between $4.60 and $4.64 billion, with analysts expecting earnings per share of $5.36, indicating significant upside potential. Risks include slower growth in consumables and a maturing NovaSeq X migration, which could delay revenue growth as customer expansion slows.
Following Illumina's report on strong demand for its NovaSeq X instruments and consumables, the stock is trading at USD 269.92 on Pluang as of Oct 22, 2026 21:31 WIB. The share price has declined by 4.57% in the past day, with a market capitalization of $42.71 billion. Investor interest remains skewed towards buying, with 68% of Pluang orders favoring purchases over sales.
Illumina introduced three early-access AI-driven capabilities on its BioInsight Platform—DRAGEN Ultra, Workflow Orchestrator, and Learning Cohorts—to accelerate genomic research. These tools automate sequencing workflows, prioritize genetic variants ...
Illumina, a leader in DNA sequencing technology, announced its management will participate in the UBS Global Healthcare Conference on November 10, 2026. The event includes a fireside chat webcast available on Illumina's investor website, where the co...
